Neurocrine Bio. (NBIX) PT Raised to $120 at SVB Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $142.26 -0.72%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 15
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 15
Join SI Premium – FREE
SVB Leerink analyst Marc Goodman raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $120.00 (from $105.00) while maintaining a Market Perform rating.
You May Also Be Interested In
- UCB SA (UCB:BB) (UCBJY) PT Raised to EUR340 at TD Cowen
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Tango Therapeutics Inc. (TNGX) PT Raised to $55 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
